Shanghai Junshi Biosciences Co SMA 50
What is the SMA 50 of Shanghai Junshi Biosciences Co?
The SMA 50 of Shanghai Junshi Biosciences Co., Ltd. is $2 -24.00%
What is the definition of SMA 50?
SMA 50 is an average stock price from the last 50 days calculated as an unweighted mean of the previous 50 stock closing prices.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 of companies in the Health Care sector on OTC compared to Shanghai Junshi Biosciences Co
What does Shanghai Junshi Biosciences Co do?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Companies with sma 50 similar to Shanghai Junshi Biosciences Co
- Transmetro has SMA 50 of AUD$2 -12.35%
- Ring Inc has SMA 50 of $2 -12.37%
- China Finance Investment has SMA 50 of HKD$2 -27.07%
- HKE has SMA 50 of HKD$2 -4.83%
- Innovid Corp has SMA 50 of $2 -11.22%
- Beijing Jingneng Clean Co has SMA 50 of HKD$2 -7.40%
- Shanghai Junshi Biosciences Co has SMA 50 of $2 -24.00%
- Tomson has SMA 50 of HKD$2 -0.02%
- China MeiDong Auto has SMA 50 of HKD$2 -10.81%
- Maiden Ltd has SMA 50 of $2 -16.44%
- Cambium Networks Corp has SMA 50 of $2 -10.26%
- CNNC International has SMA 50 of HKD$2 -38.10%
- Cairn Homes plc has SMA 50 of €2 -1.03%